RASP: AI 评分 44/100 — AI 分析 (4月 2026)

Actavia Life Sciences, Inc. is a biotechnology company focused on developing therapeutics for leukemia and lymphoma. The company develops small molecule drug candidates targeting acute myeloid leukemia.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Actavia Life Sciences, Inc., a biotechnology firm, focuses on developing therapeutics for leukemia and lymphoma, particularly small molecule drug candidates for acute myeloid leukemia. Operating in the competitive biotechnology sector, the company navigates the high-risk, high-reward landscape of drug development with a focus on hematological malignancies.

RASP是做什么的？

Founded in 2013 and headquartered in New York City, Actavia Life Sciences, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics for the treatment of leukemia and lymphoma. The company's primary focus is on developing small molecule drug candidates that target acute myeloid leukemia (AML), a particularly aggressive form of blood cancer. Actavia's research and development efforts are centered on identifying and validating promising drug targets and advancing preclinical candidates towards clinical trials. As a biotechnology company, Actavia operates within a complex and highly regulated environment, requiring significant investment in research, development, and clinical testing to bring its therapies to market. The company's success depends on its ability to successfully navigate the drug development process, secure regulatory approvals, and ultimately commercialize its products.

RASP的投资论点是什么？

Actavia Life Sciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing therapeutics for leukemia and lymphoma, particularly AML, addresses a significant unmet medical need. However, as of 2026-03-16, the company's market capitalization is $0.00B, and it operates with a single employee, indicating an early stage of development. A negative P/E ratio of -0.07 suggests the company is not currently profitable. The company's success hinges on its ability to advance its drug candidates through preclinical and clinical development, secure regulatory approvals, and ultimately commercialize its therapies. Investors should carefully consider the inherent risks associated with biotechnology investments, including the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

RASP在哪个行业运营？

Actavia Life Sciences, Inc. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and significant regulatory oversight. The market for leukemia and lymphoma therapeutics is substantial, driven by the prevalence of these diseases and the ongoing need for more effective treatments. Actavia competes with both established pharmaceutical companies and other biotechnology firms in the development of novel therapies. The company's success depends on its ability to differentiate its drug candidates, secure intellectual property protection, and navigate the complex regulatory landscape.

Biotechnology

Healthcare

RASP有哪些增长机遇？

Advancement of AML drug candidates: Actavia's primary growth opportunity lies in the successful development and commercialization of its small molecule drug candidates targeting acute myeloid leukemia. The global AML market is projected to reach billions of dollars, offering significant revenue potential for Actavia if its therapies prove effective and safe. Timeline: Ongoing, with preclinical and clinical milestones to be achieved.
Expansion into other hematological malignancies: Actavia could expand its pipeline to include therapeutics for other hematological malignancies beyond leukemia and lymphoma. This would broaden its addressable market and diversify its product portfolio. Timeline: Potential expansion within the next 3-5 years, contingent on successful advancement of current pipeline.
Strategic partnerships and collaborations: Actavia could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. This would provide access to additional funding, expertise, and resources. Timeline: Ongoing, with potential partnerships to be formed as pipeline progresses.
Out-licensing of drug candidates: Actavia could out-license its drug candidates to other companies for further development and commercialization. This would generate upfront and milestone payments, as well as royalties on future sales. Timeline: Potential out-licensing opportunities as pipeline progresses and clinical data becomes available.
Acquisition by a larger pharmaceutical company: Actavia could be acquired by a larger pharmaceutical company seeking to expand its oncology pipeline. This would provide a significant return on investment for Actavia's shareholders. Timeline: Potential acquisition within the next 5-7 years, contingent on successful pipeline development and clinical data.

Market capitalization of $0.00B, indicating a micro-cap company.
P/E ratio of -0.07, reflecting current lack of profitability.
Beta of -64.36, suggesting an inverse correlation with the market, but should be interpreted with caution due to the company's size and stage.
Focus on developing therapeutics for leukemia and lymphoma, addressing a significant unmet medical need.
Operates with a single employee, indicating a very early stage of development and high reliance on external resources.

RASP提供哪些产品和服务？

Develops therapeutics for the treatment of leukemia and lymphoma diseases.
Focuses on small molecule drug candidates.
Targets acute myeloid leukemia (AML).
Conducts research and development activities.
Seeks to identify and validate promising drug targets.
Advances preclinical candidates towards clinical trials.

RASP如何赚钱？

Develops and patents novel therapeutic compounds.
Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
Seeks regulatory approval from agencies such as the FDA.
May out-license or partner with larger pharmaceutical companies for commercialization.

Patients suffering from leukemia and lymphoma.
Healthcare providers who treat these patients.
Pharmaceutical companies interested in licensing or acquiring novel therapeutics.

Intellectual property protection (patents) on novel drug candidates.
Proprietary knowledge and expertise in drug discovery and development.
Potential for orphan drug designation, providing market exclusivity.
First-mover advantage in developing novel therapies for specific subtypes of leukemia and lymphoma.

什么因素可能推动RASP股价上涨？

Upcoming: Announcement of preclinical data for AML drug candidates.
Upcoming: Initiation of Phase 1 clinical trial for lead drug candidate.
Ongoing: Pursuit of strategic partnerships and collaborations.
Ongoing: Efforts to secure additional funding and investment.
Ongoing: Research and development activities to expand pipeline.

RASP的主要风险是什么？

Potential: Clinical trial failures and setbacks.
Potential: Regulatory hurdles and delays.
Potential: Competition from established pharmaceutical companies.
Potential: Inability to secure sufficient funding.
Ongoing: Limited resources and operational capacity due to small size.

RASP的核心优势是什么？

Focus on a specific therapeutic area (leukemia and lymphoma).
Development of small molecule drug candidates.
Potential for novel therapies to address unmet medical needs.
Location in New York City, providing access to talent and resources.

RASP的劣势是什么？

Early stage of development with limited resources (one employee).
Lack of revenue and profitability.
High dependence on external funding.
Significant regulatory and clinical development risks.

RASP有哪些机遇？

Advancement of drug candidates through clinical trials.
Strategic partnerships and collaborations with larger pharmaceutical companies.
Expansion into other hematological malignancies.
Out-licensing of drug candidates.

RASP面临哪些威胁？

Clinical trial failures.
Regulatory hurdles and delays.
Competition from established pharmaceutical companies.
Inability to secure sufficient funding.

RASP的竞争对手是谁？

ChromaDex Corp — Focuses on nutraceuticals and dietary supplements. — (CHNXF)
Ipix Corp. — Develops pharmaceutical products; different therapeutic focus. — (IPIX)
Leafbuyer Technologies Inc — Operates in the cannabis industry, unrelated to Actavia's focus. — (LFCOF)
Medin Technologies Inc — Manufactures medical devices, different market segment. — (MDIN)
NeuroBo Pharmaceuticals Inc — Focuses on neurodegenerative diseases; different therapeutic area. — (NBIO)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Keeren Shah
Headquarters: New York City, US
Employees: 1
Founded: 2015

AI Insight

AI analysis pending for RASP

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Actavia Life Sciences, Inc. do?

Actavia Life Sciences, Inc. is a biotechnology company focused on the development of therapeutics for leukemia and lymphoma, with a particular emphasis on acute myeloid leukemia (AML). The company's business model revolves around identifying promising drug targets, developing small molecule drug candidates, and advancing them through preclinical and clinical development. Actavia aims to address the unmet medical need for more effective treatments for these hematological malignancies.

What do analysts say about RASP stock?

As of 2026-03-16, there is no available analyst coverage or consensus for Actavia Life Sciences, Inc. (RASP). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own independent research and due diligence before making any investment decisions. Key valuation metrics, such as revenue projections and earnings estimates, are not currently available.

What are the main risks for RASP?

The main risks for Actavia Life Sciences, Inc. include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, and the inability to secure sufficient funding. As a small biotechnology company operating on the OTC market, Actavia faces significant challenges in advancing its drug candidates through the development process. The company's limited resources and operational capacity also pose risks to its ability to execute its business plan.

What is Actavia Life Sciences, Inc.'s drug pipeline status?

Actavia Life Sciences, Inc.'s drug pipeline focuses on therapeutics for leukemia and lymphoma, particularly small molecule drug candidates targeting acute myeloid leukemia (AML). As of 2026-03-16, the specific stages of development for each drug candidate are not detailed in the provided data. Investors should seek additional information regarding the company's preclinical and clinical development programs to assess the potential for future catalysts.

How does Actavia Life Sciences, Inc. plan to navigate the regulatory landscape for drug approval?

Given Actavia Life Sciences, Inc.'s focus on developing therapeutics for leukemia and lymphoma, the company will need to navigate a complex regulatory landscape to gain approval for its drug candidates. This includes conducting rigorous preclinical and clinical trials to demonstrate safety and efficacy, as well as complying with regulations set forth by agencies such as the FDA. The company may also seek orphan drug designation for its therapies, which can provide market exclusivity and other benefits.